1762 — Chunghwa Chemical Synthesis & Biotech Share Price
Last trade - 00:00- TWD2.38bn
- TWD2.80bn
- TWD804.88m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.74 | ||
| Price to Tang. Book | 0.74 | ||
| Price to Free Cashflow | 9.58 | ||
| Price to Sales | 2.55 | ||
| EV to EBITDA | 55.01 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.35% | ||
| Return on Equity | -1.6% | ||
| Operating Margin | -14.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 1,934.7 | 2,117.14 | 2,086.44 | 1,347.38 | 804.88 | 1,410 | n/a | -12.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +61.56 | +16.11 | -42.91 | -72.52 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.
Directors
- Kuo-Chiang Wang IND
- Hou-Jie Wang DRC
- I-Chen Wang Hsien CHM
- Ying-Chi Chen DGM
- Hou-Kai Wang VCH
- Arthur Kuan IND
- Shixuan Wu DRC
- Mingjie Li IND
- Wen-Yu Hsiao GMG
- Wen-Ping Wang DGM
- Zhiwei Zhang OTH
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- May 19th, 1964
- Public Since
- December 10th, 2009
- No. of Shareholders
- 55,921
- No. of Employees
- 243
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 76,918,000
- Address
- No.1, NEW TAIPEI, 238
- Web
- http://www.ccsb.com.tw
- Phone
- +886 286843318
- Auditors
- PricewaterhouseCoopers
Latest News for 1762
Upcoming Events for 1762
Q3 2026 Chunghwa Chemical Synthesis & Biotech Co Ltd Earnings Release
October 2026 Chunghwa Chemical Synthesis & Biotech Co Ltd Corporate Sales Release
November 2026 Chunghwa Chemical Synthesis & Biotech Co Ltd Corporate Sales Release
December 2026 Chunghwa Chemical Synthesis & Biotech Co Ltd Corporate Sales Release
January 2027 Chunghwa Chemical Synthesis & Biotech Co Ltd Corporate Sales Release
Q4 2026 Chunghwa Chemical Synthesis & Biotech Co Ltd Earnings Release
February 2027 Chunghwa Chemical Synthesis & Biotech Co Ltd Corporate Sales Release
March 2027 Chunghwa Chemical Synthesis & Biotech Co Ltd Corporate Sales Release
Q1 2027 Chunghwa Chemical Synthesis & Biotech Co Ltd Earnings Release
Similar to 1762
Adimmune
Taiwan Stock Exchange
BORA PHARMACEUTICALS
Taiwan Stock Exchange
BRIM BIOTECHNOLOGY
Taiwan Stock Exchange
CALIWAY BIOPHARMACEUTICALS
Taiwan Stock Exchange
Cenra
Taiwan Stock Exchange
FAQ
As of Today at 18:58 UTC, shares in Chunghwa Chemical Synthesis & Biotech are trading at TWD30.95. This share price information is delayed by 15 minutes.
Shares in Chunghwa Chemical Synthesis & Biotech last closed at TWD30.95 and the price had moved by +23.55% over the past 365 days. In terms of relative price strength the Chunghwa Chemical Synthesis & Biotech share price has underperformed the FTSE Developed Asia Pacific Index by -6.34% over the past year.
The overall consensus recommendation for Chunghwa Chemical Synthesis & Biotech is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreChunghwa Chemical Synthesis & Biotech does not currently pay a dividend.
Chunghwa Chemical Synthesis & Biotech does not currently pay a dividend.
Chunghwa Chemical Synthesis & Biotech does not currently pay a dividend.
To buy shares in Chunghwa Chemical Synthesis & Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD30.95, shares in Chunghwa Chemical Synthesis & Biotech had a market capitalisation of TWD2.38bn.
Here are the trading details for Chunghwa Chemical Synthesis & Biotech:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 1762
Based on an overall assessment of its quality, value and momentum Chunghwa Chemical Synthesis & Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Chunghwa Chemical Synthesis & Biotech is TWD125.00. That is 303.88% above the last closing price of TWD30.95.
Analysts covering Chunghwa Chemical Synthesis & Biotech currently have a consensus Earnings Per Share (EPS) forecast of TWD0.45 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chunghwa Chemical Synthesis & Biotech. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -10.86%.
As of the last closing price of TWD30.95, shares in Chunghwa Chemical Synthesis & Biotech were trading -5.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Chunghwa Chemical Synthesis & Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD30.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Chunghwa Chemical Synthesis & Biotech's management team is headed by:
- Kuo-Chiang Wang - IND
- Hou-Jie Wang - DRC
- I-Chen Wang Hsien - CHM
- Ying-Chi Chen - DGM
- Hou-Kai Wang - VCH
- Arthur Kuan - IND
- Shixuan Wu - DRC
- Mingjie Li - IND
- Wen-Yu Hsiao - GMG
- Wen-Ping Wang - DGM
- Zhiwei Zhang - OTH